PDS Biotechnology (NASDAQ:PDSB) Stock Price Down 5.9% – Here’s Why

PDS Biotechnology Corporation (NASDAQ:PDSB)’s share price was down 5.9% during mid-day trading on Wednesday . The company traded as low as $0.7102 and last traded at $0.7155. Approximately 108,284 shares traded hands during trading, a decline of 67% from the average session volume of 330,208 shares. The stock had previously closed at $0.76.

Analyst Upgrades and Downgrades

PDSB has been the topic of several recent analyst reports. HC Wainwright reissued a “buy” rating and issued a $15.00 target price on shares of PDS Biotechnology in a report on Wednesday, April 15th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of PDS Biotechnology in a report on Friday, July 17th. Finally, Wall Street Zen raised PDS Biotechnology from a “sell” rating to a “hold” rating in a report on Saturday, April 4th. Two investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, PDS Biotechnology presently has an average rating of “Hold” and an average target price of $9.00.

PDS Biotechnology Trading Down 5.9%

The business’s 50-day moving average price is $0.97 and its two-hundred day moving average price is $0.89. The company has a market capitalization of $40.01 million, a P/E ratio of -1.07 and a beta of 1.59. The company has a debt-to-equity ratio of 2.73, a current ratio of 2.26 and a quick ratio of 2.26.

PDS Biotechnology (NASDAQ:PDSB) last posted its earnings results on Wednesday, May 13th. The company reported ($0.13) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.15) by $0.02. As a group, analysts forecast that PDS Biotechnology Corporation will post -0.52 EPS for the current fiscal year.

Institutional Trading of PDS Biotechnology

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Marshall Wace LLP bought a new stake in PDS Biotechnology in the 2nd quarter valued at $91,000. Jane Street Group LLC acquired a new stake in shares of PDS Biotechnology during the 2nd quarter worth about $92,000. Squarepoint Ops LLC boosted its holdings in shares of PDS Biotechnology by 116.1% during the 3rd quarter. Squarepoint Ops LLC now owns 291,627 shares of the company’s stock worth $295,000 after buying an additional 156,662 shares during the period. Susquehanna International Group LLP boosted its holdings in shares of PDS Biotechnology by 603.7% during the 3rd quarter. Susquehanna International Group LLP now owns 94,344 shares of the company’s stock worth $95,000 after buying an additional 80,937 shares during the period. Finally, Tempus Wealth Planning LLC grew its stake in PDS Biotechnology by 29.3% in the 4th quarter. Tempus Wealth Planning LLC now owns 61,800 shares of the company’s stock valued at $48,000 after buying an additional 14,000 shares during the last quarter. 26.84% of the stock is owned by institutional investors.

PDS Biotechnology Company Profile

PDS Biotechnology Group, Inc is a clinical‐stage immunotherapy company focused on the development of targeted treatments for oncology and infectious diseases. The company’s proprietary Amplivant™ adjuvant platform leverages Toll-like receptor 3 activation to prime antigen‐presenting cells, directing robust immune responses against defined tumor and viral antigens. Its lead therapeutic vaccine candidate, PDS‐0101, is designed to treat HPV16‐positive cancers and is being evaluated both as a monotherapy and in combination with checkpoint inhibitors in ongoing Phase 1/2 clinical trials.

Beyond its HPV‐focused program, PDS Biotechnology is advancing a diversified pipeline of immunotherapies incorporating its Amplivant platform.